[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
Identifieur interne : 000149 ( Main/Exploration ); précédent : 000148; suivant : 000150[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
Auteurs : S. Defoort-Dhellemmes [France]Source :
- Journal francais d'ophtalmologie [ 1773-0597 ] ; 2020.
Descripteurs français
- KwdFr :
- Agents de maintien de la densité osseuse (effets indésirables), Antipaludiques (administration et posologie), Antipaludiques (effets indésirables), Betacoronavirus (MeSH), Contre-indications aux médicaments (MeSH), Facteurs de risque (MeSH), Humains (MeSH), Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Insuffisance rénale (complications), Obésité (complications), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Rétinopathies (induit chimiquement), Tamoxifène (effets indésirables).
- MESH :
- administration et posologie : Antipaludiques, Hydroxychloroquine.
- effets indésirables : Agents de maintien de la densité osseuse, Antipaludiques, Hydroxychloroquine, Insuffisance rénale, Obésité, Tamoxifène.
- induit chimiquement : Rétinopathies.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Contre-indications aux médicaments, Facteurs de risque, Humains, Pandémies.
English descriptors
- KwdEn :
- Antimalarials (administration & dosage), Antimalarials (adverse effects), Betacoronavirus (MeSH), Bone Density Conservation Agents (adverse effects), Contraindications, Drug (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Obesity (complications), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Renal Insufficiency (complications), Retinal Diseases (chemically induced), Risk Factors (MeSH), Tamoxifen (adverse effects).
- MESH :
- chemical , administration & dosage : Antimalarials, Hydroxychloroquine.
- chemical , adverse effects : Antimalarials, Bone Density Conservation Agents, Hydroxychloroquine, Tamoxifen.
- chemically induced : Retinal Diseases.
- complications : Obesity, Renal Insufficiency.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Contraindications, Drug, Humans, Pandemics, Risk Factors.
DOI: 10.1016/j.jfo.2020.04.014
PubMed: 32451138
PubMed Central: PMC7190467
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]</title><author><name sortKey="Defoort Dhellemmes, S" sort="Defoort Dhellemmes, S" uniqKey="Defoort Dhellemmes S" first="S" last="Defoort-Dhellemmes">S. Defoort-Dhellemmes</name><affiliation wicri:level="3"><nlm:affiliation>Cite Hospitalière, 2, avenue Oscar-Lambret, 59000 Lille, France. Electronic address: sabine.defoort@chru-lille.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Cite Hospitalière, 2, avenue Oscar-Lambret, 59000 Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32451138</idno><idno type="pmid">32451138</idno><idno type="doi">10.1016/j.jfo.2020.04.014</idno><idno type="pmc">PMC7190467</idno><idno type="wicri:Area/Main/Corpus">001124</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001124</idno><idno type="wicri:Area/Main/Curation">001124</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001124</idno><idno type="wicri:Area/Main/Exploration">001124</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]</title><author><name sortKey="Defoort Dhellemmes, S" sort="Defoort Dhellemmes, S" uniqKey="Defoort Dhellemmes S" first="S" last="Defoort-Dhellemmes">S. Defoort-Dhellemmes</name><affiliation wicri:level="3"><nlm:affiliation>Cite Hospitalière, 2, avenue Oscar-Lambret, 59000 Lille, France. Electronic address: sabine.defoort@chru-lille.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Cite Hospitalière, 2, avenue Oscar-Lambret, 59000 Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal francais d'ophtalmologie</title><idno type="eISSN">1773-0597</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarials (administration & dosage)</term><term>Antimalarials (adverse effects)</term><term>Betacoronavirus (MeSH)</term><term>Bone Density Conservation Agents (adverse effects)</term><term>Contraindications, Drug (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Obesity (complications)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Renal Insufficiency (complications)</term><term>Retinal Diseases (chemically induced)</term><term>Risk Factors (MeSH)</term><term>Tamoxifen (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents de maintien de la densité osseuse (effets indésirables)</term><term>Antipaludiques (administration et posologie)</term><term>Antipaludiques (effets indésirables)</term><term>Betacoronavirus (MeSH)</term><term>Contre-indications aux médicaments (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (administration et posologie)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Insuffisance rénale (complications)</term><term>Obésité (complications)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Rétinopathies (induit chimiquement)</term><term>Tamoxifène (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antimalarials</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antimalarials</term><term>Bone Density Conservation Agents</term><term>Hydroxychloroquine</term><term>Tamoxifen</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antipaludiques</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Retinal Diseases</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Obesity</term><term>Renal Insufficiency</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term><term>Antipaludiques</term><term>Hydroxychloroquine</term><term>Insuffisance rénale</term><term>Obésité</term><term>Tamoxifène</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Rétinopathies</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Contraindications, Drug</term><term>Humans</term><term>Pandemics</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Contre-indications aux médicaments</term><term>Facteurs de risque</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32451138</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1773-0597</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal francais d'ophtalmologie</Title><ISOAbbreviation>J Fr Ophtalmol</ISOAbbreviation></Journal><ArticleTitle>[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]</ArticleTitle><Pagination><MedlinePgn>548-549</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0181-5512(20)30178-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jfo.2020.04.014</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Defoort-Dhellemmes</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cite Hospitalière, 2, avenue Oscar-Lambret, 59000 Lille, France. Electronic address: sabine.defoort@chru-lille.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><VernacularTitle>Faut-il une surveillance ophtalmologique en cas de traitement de courte durée par hydroxychloroquine en cette période d’épidémie au COVID-19 ?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>J Fr Ophtalmol</MedlineTA><NlmUniqueID>7804128</NlmUniqueID><ISSNLinking>0181-5512</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>094ZI81Y45</RegistryNumber><NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075203" MajorTopicYN="N">Contraindications, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051437" MajorTopicYN="N">Renal Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012164" MajorTopicYN="N">Retinal Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32451138</ArticleId><ArticleId IdType="pii">S0181-5512(20)30178-9</ArticleId><ArticleId IdType="doi">10.1016/j.jfo.2020.04.014</ArticleId><ArticleId IdType="pmc">PMC7190467</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li></region><settlement><li>Lille</li></settlement></list><tree><country name="France"><region name="Hauts-de-France"><name sortKey="Defoort Dhellemmes, S" sort="Defoort Dhellemmes, S" uniqKey="Defoort Dhellemmes S" first="S" last="Defoort-Dhellemmes">S. Defoort-Dhellemmes</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000149 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000149 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32451138
|texte= [Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32451138" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |